Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data
Article (Faculty180)
R Murad, Mohamed; Awashra, Ameer; S Elgendy, Mohamed; Kasem, Ahmed Wahda W; Shubietah, Abdalhakim; Safi, Fadi
description
Pulmonary arterial hypertension (PAH) remains progressive despite contemporary background therapy. Sotatercept is a novel activin signaling inhibitor that targets pulmonary vascular remodeling and may improve clinical and hemodynamic outcomes.
